Eli Lilly and Company LLY
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 6.45B | 7.10B | 7.40B | 6.64B | 5.58B |
| Total Depreciation and Amortization | 545.00M | 534.00M | 509.00M | 585.70M | 470.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.97B | 3.73B | -908.00M | -324.70M | 1.58B |
| Change in Net Operating Assets | 435.00M | -670.00M | -1.66B | -3.67B | 1.21B |
| Cash from Operations | 11.40B | 10.69B | 5.33B | 3.22B | 8.84B |
| Capital Expenditure | -3.18B | -2.93B | -2.33B | -2.55B | -2.09B |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -887.00M | -8.75B | -1.06B | -111.60M | -549.00M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -4.23B | -3.72B | -532.00M | -143.90M | -346.00M |
| Cash from Investing | -8.30B | -15.40B | -3.92B | -2.80B | -2.98B |
| Total Debt Issued | -5.28B | 12.45B | 1.78B | -200.00K | 6.71B |
| Total Debt Repaid | 0.00 | -873.00M | -750.00M | -300.00K | -4.09B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -377.00M | -1.60B | -2.36B | -1.51B | -708.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1.54B | -1.55B | -1.55B | -1.35B | -1.35B |
| Other Financing Activities | -17.00M | -4.00M | -591.00M | -25.10M | -29.00M |
| Cash from Financing | -7.22B | 8.43B | -3.47B | -2.88B | 531.00M |
| Foreign Exchange rate Adjustments | 56.00M | -52.00M | 67.00M | -67.10M | 32.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.07B | 3.67B | -1.99B | -2.52B | 6.42B |